NO176481C - Fremgangsmåte for fremstilling av et fusjonsprotein - Google Patents

Fremgangsmåte for fremstilling av et fusjonsprotein

Info

Publication number: NO176481C
Authority: NO; Norway
Prior art keywords: new; preparation; fusion protein; derivs; terminally
Prior art date: 1985-11-27

Application number

NO864759A

Other languages

English (en)

Other versions

NO176481B (no

NO864759D0 (no

Inventor

Paul Habermann

Friedrich Wengenmayer

Original Assignee

Hoechst Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-11-27

Filing date

1986-11-26

Publication date

1995-04-12

1986-11-26 Application filed by Hoechst Ag filed Critical Hoechst Ag

1986-11-26 Publication of NO864759D0 publication Critical patent/NO864759D0/no

1995-01-02 Publication of NO176481B publication Critical patent/NO176481B/no

1995-04-12 Publication of NO176481C publication Critical patent/NO176481C/no

Links

108020001507 fusion proteins Proteins 0.000 title abstract 3
102000037865 fusion proteins Human genes 0.000 abstract 2
239000013598 vector Substances 0.000 abstract 2
102000007625 Hirudins Human genes 0.000 abstract 1
108010007267 Hirudins Proteins 0.000 abstract 1
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 abstract 1
102000000588 Interleukin-2 Human genes 0.000 abstract 1
108010002350 Interleukin-2 Proteins 0.000 abstract 1
101150010487 are gene Proteins 0.000 abstract 1
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 abstract 1
229940006607 hirudin Drugs 0.000 abstract 1
102000055277 human IL2 Human genes 0.000 abstract 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Physics & Mathematics (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Tropical Medicine & Parasitology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Materials For Medical Uses (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

NO864759A 1985-11-27 1986-11-26 Fremgangsmåte for fremstilling av et fusjonsprotein NO176481C (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19853541856 DE3541856A1 (de)	1985-11-27	1985-11-27	Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens

Publications (3)

Publication Number	Publication Date
NO864759D0 NO864759D0 (no)	1986-11-26
NO176481B NO176481B (no)	1995-01-02
NO176481C true NO176481C (no)	1995-04-12

Family

ID=6286938

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO864759A NO176481C (no)	1985-11-27	1986-11-26	Fremgangsmåte for fremstilling av et fusjonsprotein

Country Status (17)

Country	Link
EP (3)	EP0468539B1 (no)
JP (1)	JP2566933B2 (no)
KR (1)	KR950000300B1 (no)
AT (2)	ATE127841T1 (no)
AU (1)	AU595262B2 (no)
CA (1)	CA1341203C (no)
DE (4)	DE3541856A1 (no)
DK (2)	DK172064B1 (no)
ES (3)	ES2032378T3 (no)
FI (1)	FI93471C (no)
GR (1)	GR3005042T3 (no)
HU (1)	HU203579B (no)
IE (1)	IE59488B1 (no)
IL (1)	IL80755A0 (no)
NO (1)	NO176481C (no)
PT (1)	PT83813B (no)
ZA (1)	ZA868943B (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3125021A (en) *	1955-11-14	1964-03-17		Smooth
ATE64956T1 (de) *	1984-06-14	1991-07-15	Ciba Geigy Ag	Verfahren zur herstellung von thrombininhibitoren.
DE3545568A1 (de) *	1985-12-21	1987-07-16	Hoechst Ag	Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung
DE3712985A1 (de) *	1987-04-16	1988-11-03	Hoechst Ag	Bifunktionelle proteine
DE3819079A1 (de) *	1988-06-04	1989-12-07	Hoechst Ag	Hirudin-derivate mit verzoegerter wirkung
DE3835815A1 (de) *	1988-10-21	1990-04-26	Hoechst Ag	Neue isohirudine
DE3844211A1 (de) *	1988-12-29	1990-07-05	Hoechst Ag	Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US5179196A (en) *	1989-05-04	1993-01-12	Sri International	Purification of proteins employing ctap-iii fusions
WO1991000912A1 (en) *	1989-07-07	1991-01-24	Massachusetts Institute Of Technology	Production and use of hybrid protease inhibitors
CU22222A1 (es) *	1989-08-03	1995-01-31	Cigb	Procedimiento para la expresion de proteinas heterologicas producidas de forma fusionada en escherichia coli, su uso, vectores de expresion y cepas recombinantes
GB8927722D0 (en) *	1989-12-07	1990-02-07	British Bio Technology	Proteins and nucleic acids
DE3942580A1 (de) *	1989-12-22	1991-06-27	Basf Ag	Verfahren zur herstellung von hirudin
US5270181A (en) *	1991-02-06	1993-12-14	Genetics Institute, Inc.	Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
DE4140381A1 (de) *	1991-12-07	1993-06-09	Hoechst Ag, 6230 Frankfurt, De	Neue synthetische isohirudine mit verbesserter stabilitaet
DE4404168A1 (de) *	1994-02-10	1995-08-17	Hoechst Ag	Hirudinderivate und Verfahren zu deren Herstellung
DE59711533D1 (de)	1996-07-26	2004-05-27	Aventis Pharma Gmbh	Insulinderivate mit erhöhter Zinkbindung
DE19726167B4 (de)	1997-06-20	2008-01-24	Sanofi-Aventis Deutschland Gmbh	Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
DE19825447A1 (de)	1998-06-06	1999-12-09	Hoechst Marion Roussel De Gmbh	Neue Insulinanaloga mit erhöhter Zinkbildung
DE10033195A1 (de) *	2000-07-07	2002-03-21	Aventis Pharma Gmbh	Bifunktionale Fusionsproteine aus Hirudin und TAP
US7202059B2 (en)	2001-02-20	2007-04-10	Sanofi-Aventis Deutschland Gmbh	Fusion proteins capable of being secreted into a fermentation medium
US7638618B2 (en)	2001-02-20	2009-12-29	Sanofi-Aventis Deutschland Gmbh	Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest
DE10114178A1 (de)	2001-03-23	2002-10-10	Aventis Pharma Gmbh	Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE10227232A1 (de)	2002-06-18	2004-01-15	Aventis Pharma Deutschland Gmbh	Saure Insulinzubereitungen mit verbesserter Stabilität
PT3228320T (pt)	2008-10-17	2020-03-26	Sanofi Aventis Deutschland	Combinação de uma insulina e de um agonista do glp-1
KR101853606B1 (ko)	2009-07-06	2018-05-03	사노피-아벤티스 도이칠란트 게엠베하	메티오닌을 함유하는 수성 인슐린 제제
KR101337322B1 (ko)	2009-11-13	2013-12-06	사노피-아벤티스 도이칠란트 게엠베하	Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
DK2498802T3 (en)	2009-11-13	2015-04-13	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
ES2606554T3 (es)	2010-08-30	2017-03-24	Sanofi-Aventis Deutschland Gmbh	Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
PL2750699T3 (pl)	2011-08-29	2015-12-31	Sanofi Aventis Deutschland	Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2
AR087744A1 (es)	2011-09-01	2014-04-16	Sanofi Aventis Deutschland	Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
AU2015359376B2 (en)	2014-12-12	2021-09-09	Sanofi-Aventis Deutschland Gmbh	Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
KR20200080747A (ko)	2018-12-27	2020-07-07	주식회사 폴루스	인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법
KR20200080748A (ko)	2018-12-27	2020-07-07	주식회사 폴루스	음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1985000817A1 (en) *	1983-08-10	1985-02-28	Amgen	Microbial expression of interleukin ii
DK108685A (da) *	1984-03-19	1985-09-20	Fujisawa Pharmaceutical Co	Vaekstfaktor i
WO1985004418A1 (fr) *	1984-03-27	1985-10-10	Transgene S.A.	Vecteurs d'expression de l'hirudine, cellules transformees et procede de preparation de l'hirudine
EP0158198A1 (en) *	1984-03-29	1985-10-16	Takeda Chemical Industries, Ltd.	DNA and use thereof
DE3429430A1 (de) *	1984-08-10	1986-02-20	Hoechst Ag, 6230 Frankfurt	Gentechnologisches verfahren zur herstellung von hirudin und mittel zur durchfuehrung dieses verfahrens
DE3526995A1 (de) *	1985-07-27	1987-02-05	Hoechst Ag	Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung
US4865974A (en) *	1985-09-20	1989-09-12	Cetus Corporation	Bacterial methionine N-terminal peptidase
CA1297003C (en) *	1985-09-20	1992-03-10	Jack H. Nunberg	Composition and method for treating animals

1985
- 1985-11-27 DE DE19853541856 patent/DE3541856A1/de not_active Withdrawn
1986
- 1986-11-21 AT AT91114411T patent/ATE127841T1/de not_active IP Right Cessation
- 1986-11-21 EP EP91114411A patent/EP0468539B1/de not_active Expired - Lifetime
- 1986-11-21 ES ES198686116140T patent/ES2032378T3/es not_active Expired - Lifetime
- 1986-11-21 DE DE3650396T patent/DE3650396D1/de not_active Expired - Lifetime
- 1986-11-21 EP EP91114412A patent/EP0464867B1/de not_active Expired - Lifetime
- 1986-11-21 ES ES91114411T patent/ES2077747T3/es not_active Expired - Lifetime
- 1986-11-21 ES ES91114412T patent/ES2073081T3/es not_active Expired - Lifetime
- 1986-11-21 DE DE8686116140T patent/DE3684892D1/de not_active Expired - Lifetime
- 1986-11-21 DE DE3650322T patent/DE3650322D1/de not_active Expired - Lifetime
- 1986-11-21 EP EP86116140A patent/EP0227938B1/de not_active Expired - Lifetime
- 1986-11-21 AT AT91114412T patent/ATE122397T1/de not_active IP Right Cessation
- 1986-11-25 FI FI864798A patent/FI93471C/fi not_active IP Right Cessation
- 1986-11-25 HU HU864872A patent/HU203579B/hu not_active IP Right Cessation
- 1986-11-25 IL IL80755A patent/IL80755A0/xx unknown
- 1986-11-26 KR KR1019860009990A patent/KR950000300B1/ko not_active Expired - Fee Related
- 1986-11-26 NO NO864759A patent/NO176481C/no unknown
- 1986-11-26 CA CA000523857A patent/CA1341203C/en not_active Expired - Fee Related
- 1986-11-26 DK DK568586A patent/DK172064B1/da not_active IP Right Cessation
- 1986-11-26 AU AU65693/86A patent/AU595262B2/en not_active Ceased
- 1986-11-26 IE IE311986A patent/IE59488B1/en not_active IP Right Cessation
- 1986-11-26 ZA ZA868943A patent/ZA868943B/xx unknown
- 1986-11-26 JP JP61281621A patent/JP2566933B2/ja not_active Expired - Lifetime
- 1986-11-26 PT PT83813A patent/PT83813B/pt not_active IP Right Cessation
1992
- 1992-04-21 DK DK052292A patent/DK172210B1/da not_active IP Right Cessation
- 1992-06-26 GR GR920401111T patent/GR3005042T3/el unknown

Also Published As

Publication number	Publication date
CA1341203C (en)	2001-03-13
KR870005098A (ko)	1987-06-04
ATE127841T1 (de)	1995-09-15
ES2032378T3 (es)	1993-02-16
FI93471B (fi)	1994-12-30
NO176481B (no)	1995-01-02
PT83813B (pt)	1989-06-30
HUT43642A (en)	1987-11-30
EP0468539A1 (de)	1992-01-29
FI93471C (fi)	1995-04-10
IE59488B1 (en)	1994-03-09
DK52292A (da)	1992-04-21
DE3541856A1 (de)	1987-06-04
FI864798A0 (fi)	1986-11-25
DK172210B1 (da)	1998-01-05
ZA868943B (en)	1987-07-29
EP0227938B1 (de)	1992-04-15
JP2566933B2 (ja)	1996-12-25
EP0468539B1 (de)	1995-09-13
DE3650322D1 (de)	1995-06-14
EP0464867B1 (de)	1995-05-10
HU203579B (en)	1991-08-28
JPS62143696A (ja)	1987-06-26
KR950000300B1 (ko)	1995-01-13
AU595262B2 (en)	1990-03-29
DK52292D0 (da)	1992-04-21
PT83813A (de)	1986-12-01
NO864759D0 (no)	1986-11-26
GR3005042T3 (no)	1993-05-24
DE3684892D1 (de)	1992-05-21
DK172064B1 (da)	1997-10-06
ATE122397T1 (de)	1995-05-15
DE3650396D1 (de)	1995-10-19
DK568586D0 (da)	1986-11-26
EP0227938A3 (en)	1988-11-23
IE863119L (en)	1987-05-27
FI864798L (fi)	1987-05-28
EP0464867A1 (de)	1992-01-08
ES2077747T3 (es)	1995-12-01
EP0227938A2 (de)	1987-07-08
IL80755A0 (en)	1987-02-27
ES2073081T3 (es)	1995-08-01
AU6569386A (en)	1987-06-04
DK568586A (da)	1987-05-28

Publication	Publication Date	Title
DK52292D0 (da)	1992-04-21	Hirudinderivater
ES8402351A1 (es)	1984-02-01	Procedimiento para producir interferon inmune humano.
FI102075B1 (fi)	1998-10-15	Menetelmä valmistaa glykosyloitu tai glykosyloimaton polypeptidi, rekombinanttinukleiinihappo ja vektorit
DK601786A (da)	1986-12-12	Hidtil ukendte prokoagulationsproteiner
IL68366A0 (en)	1983-07-31	Preparation of functional human urokinase proteins
ATE302275T1 (de)	2005-09-15	Hämatopoietisches fusionsprotein multivariantes il-3 enthaltend
AU1986588A (en)	1989-01-04	Growth hormone receptor
DE3480939D1 (de)	1990-02-08	Vektoren zur transformation von hefe.
DE3686579D1 (en)	1992-10-01	Prokaryotisches expressionssystem.
DE3881023D1 (de)	1993-06-17	Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
DK288789D0 (da)	1989-06-13	Peptider og syreadditionssalte deraf, deres fremstilling og anvendelse
GB2171703B (en)	1989-11-15	Expression-secretion vector for gene expression and protein secretion, recombinant dna including the vector, and method of producing proteins by use of the re
ES8605579A1 (es)	1986-03-16	Procedimiento para preparar proteinas encarioticas, procarioticas o viricas.